U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H35NO4
Molecular Weight 425.5604
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of PIRIPROST

SMILES

CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC2=C1C=C(CCCCC(O)=O)N2C3=CC=CC=C3

InChI

InChIKey=CZIIGGQJILPHEU-HCHVXQBBSA-N
InChI=1S/C26H35NO4/c1-2-3-5-13-21(28)15-16-22-23-17-20(12-8-9-14-26(30)31)27(24(23)18-25(22)29)19-10-6-4-7-11-19/h4,6-7,10-11,15-17,21-22,25,28-29H,2-3,5,8-9,12-14,18H2,1H3,(H,30,31)/b16-15+/t21-,22+,25+/m0/s1

HIDE SMILES / InChI

Molecular Formula C26H35NO4
Molecular Weight 425.5604
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 1
Optical Activity UNSPECIFIED

Piriprost (U-60, 257) is a structural analog of prostaglandin I2 (PGI2) with low IP receptor-mediated activity. It inhibits 5-LO (5-lipoxygenase). Piriprost inhibits the release of histamine and leukotrienes, implicating its role in inflammation and allergic responses. However, it was shown, that piriprost did not influence the airway responses after allergen in asthma. Nevertheless, even more, the drug was irritant to the respiratory tract than was placebo.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P09917
Gene ID: 240.0
Gene Symbol: ALOX5
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Piriprost: a selective inhibitor of leukotriene synthesis.
1985
Effect of inhaled piriprost (U-60, 257) a novel leukotriene inhibitor, on allergen and exercise induced bronchoconstriction in asthma.
1986 Oct
Examination of the effects of piriprost (U-60,257B) on alkaline phosphatase activity of rat endometrial stromal cells in vitro.
1991 Aug

Sample Use Guides

On separate study days subjects inhaled either piriprost 1 mg or vehicle placebo, followed 15 minutes later by the PS25 allergen or exercise. The FEV1 was measured at regular intervals before and after challenge up to 60 minutes
Route of Administration: Other
In Vitro Use Guide
It was discovered, that the effects piriprost on possible in vitro decidualization may be due to inhibition of 5-lipoxygenase. Piriprost (100 microM) was found to decrease 5-hydroxyeicosatetraenoic acid (a 5-lipoxygenase product) by 53% after 72 hr which provided evidence that 5-lipoxygenase was being inhibited by piriprost. Three microM PGE2 or 20 microM carba-prostacyclin (CP), an analogue of PGI2, maximally increased (p less than 0.01) ALP activity at 72 hr and the further addition of 100 microM piriprost to PGE2 or CP caused an additional, additive increase in ALP activity. This indicated that the mechanism of action of piriprost was probably different from that of PGE2 or PGI2. The possibility that piriprost was shunting arachidonic acid into PG production was examined. The effects of the combination of 100 microM piriprost and 10 microM IM were statistically additive, suggesting that the effects of piriprost were not due to an increase in PG production.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:43:01 GMT 2023
Edited
by admin
on Fri Dec 15 15:43:01 GMT 2023
Record UNII
R802O5NILK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIRIPROST
INN   MART.   USAN  
USAN   INN  
Official Name English
U-60257
Code English
U-60,257
Code English
PIRIPROST [MART.]
Common Name English
(4R,5R)-1,4,5,6-Tetrahydro-5-hydroxy-4-[(E)-(3S)-3-hydroxy-1-octenyl]-1-phenylcyclopenta[b]pyrrole-2-valeric acid
Systematic Name English
piriprost [INN]
Common Name English
CYCLOPENTA(B)PYRROLE-2-PENTANOIC ACID, 1,4,5,6-TETRAHYDRO-5-HYDROXY-4-(3-HYDROXY-1-OCTENYL)-1-PHENYL-, (4R-(4.ALPHA.(1E,3S*),5.BETA.))-
Common Name English
PIRIPROST [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C78568
Created by admin on Fri Dec 15 15:43:01 GMT 2023 , Edited by admin on Fri Dec 15 15:43:01 GMT 2023
NCI_THESAURUS C1322
Created by admin on Fri Dec 15 15:43:01 GMT 2023 , Edited by admin on Fri Dec 15 15:43:01 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C66425
Created by admin on Fri Dec 15 15:43:01 GMT 2023 , Edited by admin on Fri Dec 15 15:43:01 GMT 2023
PRIMARY
USAN
T-99
Created by admin on Fri Dec 15 15:43:01 GMT 2023 , Edited by admin on Fri Dec 15 15:43:01 GMT 2023
PRIMARY
CAS
79672-88-1
Created by admin on Fri Dec 15 15:43:01 GMT 2023 , Edited by admin on Fri Dec 15 15:43:01 GMT 2023
PRIMARY
FDA UNII
R802O5NILK
Created by admin on Fri Dec 15 15:43:01 GMT 2023 , Edited by admin on Fri Dec 15 15:43:01 GMT 2023
PRIMARY
EVMPD
SUB09917MIG
Created by admin on Fri Dec 15 15:43:01 GMT 2023 , Edited by admin on Fri Dec 15 15:43:01 GMT 2023
PRIMARY
SMS_ID
100000081650
Created by admin on Fri Dec 15 15:43:01 GMT 2023 , Edited by admin on Fri Dec 15 15:43:01 GMT 2023
PRIMARY
PUBCHEM
6437373
Created by admin on Fri Dec 15 15:43:01 GMT 2023 , Edited by admin on Fri Dec 15 15:43:01 GMT 2023
PRIMARY
MESH
C035296
Created by admin on Fri Dec 15 15:43:01 GMT 2023 , Edited by admin on Fri Dec 15 15:43:01 GMT 2023
PRIMARY
INN
5546
Created by admin on Fri Dec 15 15:43:01 GMT 2023 , Edited by admin on Fri Dec 15 15:43:01 GMT 2023
PRIMARY
ChEMBL
CHEMBL2105239
Created by admin on Fri Dec 15 15:43:01 GMT 2023 , Edited by admin on Fri Dec 15 15:43:01 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY